$ALDX
Aldeyra Therapeutics, Inc.

2021 Q3 Form 10-Q Financial Statement

#000095017021000925 Filed on August 05, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.547M $3.069M $2.220M
YoY Change 12.69% 38.23% -28.85%
% of Gross Profit
Research & Development $12.89M $11.47M $4.886M
YoY Change 110.23% 134.85% -54.19%
% of Gross Profit
Depreciation & Amortization $68.35K $64.56K $70.00K
YoY Change -14.56% -7.77% 133.33%
% of Gross Profit
Operating Expenses $12.89M $11.47M $4.886M
YoY Change 110.23% 134.85% -54.19%
Operating Profit -$15.44M -$14.54M -$7.106M
YoY Change 84.06% 104.66% -48.25%
Interest Expense $413.1K $433.5K $486.0K
YoY Change -15.55% -10.82% 1596.56%
% of Operating Profit
Other Income/Expense, Net -$353.8K -$393.8K -$414.3K
YoY Change -26.9% -4.95% -202.49%
Pretax Income -$15.79M -$14.94M -$7.520M
YoY Change 78.01% 98.63% -43.57%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$15.79M -$14.94M -$7.520M
YoY Change 78.01% 98.62% -43.57%
Net Earnings / Revenue
Basic Earnings Per Share -$0.27 -$0.28
Diluted Earnings Per Share -$272.2K -$0.28 -$249.7K
COMMON SHARES
Basic Shares Outstanding 57.86M 54.28M
Diluted Shares Outstanding 58.02M 54.28M

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $241.4M $249.7M $66.19M
YoY Change 180.01% 277.31% -4.7%
Cash & Equivalents $241.4M $249.7M $60.69M
Short-Term Investments $0.00 $0.00 $5.501M
Other Short-Term Assets $5.403M $6.522M $5.200M
YoY Change 170.16% 25.42% 52.94%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $246.8M $256.3M $71.40M
YoY Change 179.81% 258.91% -2.0%
LONG-TERM ASSETS
Property, Plant & Equipment $39.61K $48.08K $200.0K
YoY Change -50.15% -75.96% 1.79%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $445.6K $166.5K $200.0K
YoY Change 238.49% -16.76% -79.66%
TOTAL ASSETS
Total Short-Term Assets $246.8M $256.3M $71.40M
Total Long-Term Assets $445.6K $166.5K $200.0K
Total Assets $247.2M $256.4M $71.60M
YoY Change 179.9% 258.14% -3.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $467.9K $1.094M $200.0K
YoY Change 277.67% 447.23% -92.79%
Accrued Expenses $11.25M $6.196M $3.694M
YoY Change 180.0% 67.76% 8.51%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $900.0K
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $11.94M $7.409M $4.900M
YoY Change 83.73% 51.21% -23.31%
LONG-TERM LIABILITIES
Long-Term Debt $15.42M $15.34M $13.92M
YoY Change 21.49% 10.21%
Other Long-Term Liabilities $184.6K
YoY Change
Total Long-Term Liabilities $15.42M $15.34M $13.92M
YoY Change 21.49% 10.21% 13817.18%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.94M $7.409M $4.900M
Total Long-Term Liabilities $15.42M $15.34M $13.92M
Total Liabilities $27.55M $22.75M $18.80M
YoY Change 43.48% 21.0% 188.98%
SHAREHOLDERS EQUITY
Retained Earnings -$278.9M -$263.1M
YoY Change 23.63%
Common Stock $498.6M $496.8M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $219.7M $233.7M $52.79M
YoY Change
Total Liabilities & Shareholders Equity $247.2M $256.4M $71.60M
YoY Change 179.9% 258.14% -3.03%

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$15.79M -$14.94M -$7.520M
YoY Change 78.01% 98.62% -43.57%
Depreciation, Depletion And Amortization $68.35K $64.56K $70.00K
YoY Change -14.56% -7.77% 133.33%
Cash From Operating Activities -$8.434M -$9.074M -$7.580M
YoY Change 35.16% 19.71% -40.83%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $2.190K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $17.30M
YoY Change -100.0% -100.0% 118.16%
Cash From Investing Activities $0.00 $2.190K $17.30M
YoY Change -100.0% -99.99% 118.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 63.78K 120.4M 12.43M
YoY Change -99.76% 868.4% -124400.0%
NET CHANGE
Cash From Operating Activities -8.434M -9.074M -7.580M
Cash From Investing Activities 0.000 2.190K 17.30M
Cash From Financing Activities 63.78K 120.4M 12.43M
Net Change In Cash -8.370M 111.3M 22.15M
YoY Change -132.85% 402.49% -552.97%
FREE CASH FLOW
Cash From Operating Activities -$8.434M -$9.074M -$7.580M
Capital Expenditures $0.00 $2.190K $0.00
Free Cash Flow -$8.434M -$9.076M -$7.580M
YoY Change 35.16% 19.74% -40.78%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001341235
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36332
dei Entity Registrant Name
EntityRegistrantName
ALDEYRA THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-1968197
dei Entity Address Address Line1
EntityAddressAddressLine1
131 Hartwell Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 320
dei Entity Address City Or Town
EntityAddressCityOrTown
Lexington
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02421
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
761-4904
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
ALDX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
57864035
CY2021Q2 aldx Cash And Money Market Funds
CashAndMoneyMarketFunds
124739010
CY2020Q4 aldx Cash And Money Market Funds
CashAndMoneyMarketFunds
52858311
CY2021Q2 aldx Cash Equivalent Reverse Repurchase Agreement
CashEquivalentReverseRepurchaseAgreement
125000000
CY2020Q4 aldx Cash Equivalent Reverse Repurchase Agreement
CashEquivalentReverseRepurchaseAgreement
25000000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6521718
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5200957
CY2021Q2 us-gaap Assets Current
AssetsCurrent
256260728
CY2020Q4 us-gaap Assets Current
AssetsCurrent
83059268
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
118401
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
233310
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
48083
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
59925
CY2021Q2 us-gaap Assets
Assets
256427212
CY2020Q4 us-gaap Assets
Assets
83352503
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1094461
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
381638
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6196300
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8134765
CY2021Q2 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
0
CY2020Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
3659776
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
118401
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
233310
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
7409162
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12409489
CY2021Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15338105
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
11434456
CY2021Q2 us-gaap Liabilities
Liabilities
22747267
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19200788
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11519478
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3068652
CY2020Q4 us-gaap Liabilities
Liabilities
23843945
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2220003
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6173355
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5224844
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
57997345
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
57997345
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38667491
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38667491
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
57997
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
38667
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
496764448
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
296385619
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-263142500
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-236915728
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
233679945
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
59508558
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
256427212
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
83352503
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11474446
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4885875
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-14543098
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7105878
us-gaap Operating Income Loss
OperatingIncomeLoss
-25374143
us-gaap Operating Income Loss
OperatingIncomeLoss
-16744322
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
39665
CY2020Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
71710
us-gaap Investment Income Interest
InvestmentIncomeInterest
63427
us-gaap Investment Income Interest
InvestmentIncomeInterest
281809
CY2021Q2 us-gaap Interest Expense
InterestExpense
433477
CY2020Q2 us-gaap Interest Expense
InterestExpense
486048
us-gaap Interest Expense
InterestExpense
916056
us-gaap Interest Expense
InterestExpense
925863
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-393812
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-414338
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-852629
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-644054
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-14936910
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-7520216
us-gaap Net Income Loss
NetIncomeLoss
-26226772
us-gaap Net Income Loss
NetIncomeLoss
-17388376
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.52
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
54280393
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30118456
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
49979545
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29586148
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-14936910
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-7520216
us-gaap Net Income Loss
NetIncomeLoss
-26226772
us-gaap Net Income Loss
NetIncomeLoss
-17388376
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-52840
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1112
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-52840
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1112
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14936910
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7573056
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26226772
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17389488
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
59508558
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3465555
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
189811611
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4611127
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
9875
aldx Net Loss
NetLoss
-26226772
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
233679945
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
48082317
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3696041
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
18270488
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
60419
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
69889
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1112
aldx Net Loss
NetLoss
-17388376
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
52789666
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
126074472
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2173385
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
119762161
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
606837
CY2021Q2 aldx Net Loss
NetLoss
-14936910
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
233679945
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
43472520
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1742389
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
15097664
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
50149
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-52840
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
189811611
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
15547592
CY2020Q2 aldx Net Loss
NetLoss
-7520216
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
52789666
us-gaap Profit Loss
ProfitLoss
-26226772
us-gaap Profit Loss
ProfitLoss
-17388376
us-gaap Share Based Compensation
ShareBasedCompensation
4705218
us-gaap Share Based Compensation
ShareBasedCompensation
3696041
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
243873
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
283010
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-87452
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
134557
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
144687
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1254761
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-705371
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
712823
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-591613
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-859046
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-8289732
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22544108
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22938806
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7806
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
0
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
5776090
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
29300000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7806
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
23523910
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4611127
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
60419
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
9875
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
69889
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
194432613
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15677900
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
171880699
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
16263004
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
77858311
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
44425830
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
249739010
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60688834
us-gaap Interest Paid Net
InterestPaidNet
681333
us-gaap Interest Paid Net
InterestPaidNet
693875
aldx Offering Costs Not Yet Paid
OfferingCostsNotYetPaid
66000
aldx Offering Costs Not Yet Paid
OfferingCostsNotYetPaid
0
aldx Receivable For Proceeds From The Issuance Of Common Stock
ReceivableForProceedsFromTheIssuanceOfCommonStock
0
aldx Receivable For Proceeds From The Issuance Of Common Stock
ReceivableForProceedsFromTheIssuanceOfCommonStock
2722896
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1. NATURE OF BUSINESS</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:24.5pt;text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Aldeyra Therapeutics, Inc., together with its wholly-owned subsidiaries (the “Company” or “Aldeyra”), a Delaware corporation, is a clinical-stage biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company’s principal activities to date include raising capital and research and development activities.</span>
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:24.45pt;text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions, including fair value estimates for investments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. The Company’s management evaluates its estimates and assumptions on an ongoing basis. Management’s most significant estimates in the Company’s consolidated financial statements include, but are not limited to, estimates related to clinical trial accruals, estimates related to prepaid and accrued research and development costs, acquired in-process research and development (“IPR&amp;D”) expense, contingent liabilities, and accounting for income taxes and related valuation allowance. Although these estimates and assumptions are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5074579
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6301304
CY2021Q2 us-gaap Cash
Cash
120354749
CY2021Q2 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
4384261
CY2021Q2 aldx Cash Equivalent Reverse Repurchase Agreement
CashEquivalentReverseRepurchaseAgreement
125000000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
249739010
CY2020Q4 us-gaap Cash
Cash
23494920
CY2020Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
29363391
CY2020Q4 aldx Cash Equivalent Reverse Repurchase Agreement
CashEquivalentReverseRepurchaseAgreement
25000000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
77858311
CY2021Q2 us-gaap Marketable Securities
MarketableSecurities
0
CY2020Q4 us-gaap Marketable Securities
MarketableSecurities
0
CY2021Q2 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2020Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2021Q2 aldx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
3356819
CY2021Q2 aldx Accrued Contingent Consideration Payable In Stock Current
AccruedContingentConsiderationPayableInStockCurrent
0
CY2020Q4 aldx Accrued Contingent Consideration Payable In Stock Current
AccruedContingentConsiderationPayableInStockCurrent
2500000
CY2021Q2 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
5150067
CY2020Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
4793794
CY2021Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
74335
CY2020Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
CY2021Q2 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
1297316
CY2020Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
407163
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6521718
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5200957
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2166284
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1323138
CY2020Q4 aldx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
3944094
CY2021Q2 aldx Accrued General And Administrative Expense Current
AccruedGeneralAndAdministrativeExpenseCurrent
673197
CY2020Q4 aldx Accrued General And Administrative Expense Current
AccruedGeneralAndAdministrativeExpenseCurrent
367533
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6196300
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8134765
CY2021Q2 us-gaap Long Term Loans Payable
LongTermLoansPayable
15000000
CY2020Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
15000000
CY2021Q2 aldx End Of Term Charge
EndOfTermCharge
599008
CY2020Q4 aldx End Of Term Charge
EndOfTermCharge
445464
CY2021Q2 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
260903
CY2020Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
351232
CY2021Q2 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
0
CY2020Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
3659776
CY2021Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15338105
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
11434456
CY2020Q4 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2020Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0
CY2020Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
16042500
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
16042500
aldx Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1
CY2020 aldx Share Based Compensation Arrangement By Share Based Payment Award Granted Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedPeriod1
P4Y
CY2019 aldx Share Based Compensation Arrangement By Share Based Payment Award Granted Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedPeriod1
P4Y
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
1600000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2323561
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1742389
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4705218
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3696041
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4608311
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.73
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
830169
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.87
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
631217
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.31
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
316396
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.23
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4490867
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.68
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y1M13D
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
21334914
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2822326
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.72
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y21D
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
15865690
CY2021Q2 us-gaap Share Price
SharePrice
11.33
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
118401
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
118401
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
118401
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
121563
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
121563
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
0
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
100000
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.091
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y6M
us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
121563
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3162
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
0
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
0

Files In Submission

Name View Source Status
0000950170-21-000925-index-headers.html Edgar Link pending
0000950170-21-000925-index.html Edgar Link pending
0000950170-21-000925.txt Edgar Link pending
0000950170-21-000925-xbrl.zip Edgar Link pending
aldx-20210630.htm Edgar Link pending
aldx-20210630.xsd Edgar Link pending
aldx-20210630ex10_2.htm Edgar Link pending
aldx-20210630ex31_1.htm Edgar Link pending
aldx-20210630ex31_2.htm Edgar Link pending
aldx-20210630ex32_1.htm Edgar Link pending
aldx-20210630_cal.xml Edgar Link unprocessable
aldx-20210630_def.xml Edgar Link unprocessable
aldx-20210630_htm.xml Edgar Link completed
aldx-20210630_lab.xml Edgar Link unprocessable
aldx-20210630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending